| Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial | |
| Zhou, Ai-Ping; Bai, Yuxian; Song, Yan; Luo, Hong; Ren, Xiu-Bao; Wang, Xiuwen; Shi, Benkang; Fu, Cheng; Cheng, Ying; Liu, Jiyan | |
| 刊名 | ONCOLOGIST
 |
| 2019 | |
| 卷号 | 24期号:8 |
| 关键词 | Anlotinib Metastatic renal cell cancer Phase II clinical trial |
| ISSN号 | 1083-7159 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3595651 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Zhou, Ai-Ping,Bai, Yuxian,Song, Yan,et al. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial[J]. ONCOLOGIST,2019,24(8). |
| APA | Zhou, Ai-Ping.,Bai, Yuxian.,Song, Yan.,Luo, Hong.,Ren, Xiu-Bao.,...&Ma, Jianhui.(2019).Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.ONCOLOGIST,24(8). |
| MLA | Zhou, Ai-Ping,et al."Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial".ONCOLOGIST 24.8(2019). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论